Download PDF
Arzneimittelforschung 2012; 62(S 01): S13
DOI: 10.1055/s-0032-1324907
Symposium der Paul-Martini-Stiftung
Georg Thieme Verlag KG Stuttgart · New York

Immunotherapy in Inflammatory Bowel Diseases

M. Neurath
1   Direktor der Medizinischen Klinik 1, Universitätsklinikum Erlangen
› Author Affiliations
Further Information

Publication History

Publication Date:
04 December 2012 (online)

   Permissions and Reprints

Inflammatory bowel diseases are chronic, relapsing, inflammatory disorders of the intestine. Whereas ulcerative colitis is restricted to the colon, Crohnʼs disease can manifest itself anywhere in the alimentary tract. Ulcerative colitis is characterized by a continuous inflammation of the mucosa and submucosa in the colon. In contrast, Crohnʼs disease frequently affects all layers of the bowel wall and is associated with segmental, discontinuous inflammation.

 

  • References

  • 1 Perrier C, Rutgeerts P. Cytokine blockade in inflammatory bowel diseases. Immunotherapy 2011; 3: 1341-1352
    CrossrefPubMedSearch in Google Scholar
  • 2 Pineton de Chambrun GP, Sandborn WJ. IBD in 2011: advances in IBD management – towards a tailored approach. Nat Rev Gastroenterol Hepatol 2012; 10 9 (2) 70-72
    PubMedSearch in Google Scholar
  • 3 Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut 27.07.2012; [Epub ahead of print]
    PubMedSearch in Google Scholar
  • 4 Neurath MF, Finotto S. IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine Growth Factor Rev 2011; 22: 83-89
    CrossrefPubMedSearch in Google Scholar